These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

223 related items for PubMed ID: 2118431

  • 21. Pharmacokinetics and coronary thrombolytic properties of two human tissue-type plasminogen activator variants lacking the finger-like, growth factor-like, and first kringle domains (amino acids 6-173) in a canine model.
    Wu Z, Van de Werf F, Stassen T, Mattsson C, Pohl G, Collen D.
    J Cardiovasc Pharmacol; 1990 Aug; 16(2):197-203. PubMed ID: 1697374
    [Abstract] [Full Text] [Related]

  • 22. Single bolus administration of recombinant tissue plasminogen activator: effects on infarct related vessel patency, microvascular perfusion, and microvascular reocclusion in a canine model of thrombotic occlusion/reperfusion.
    Longridge DJ, Follenfant MJ, Ford AJ.
    Cardiovasc Res; 1991 Mar; 25(3):184-91. PubMed ID: 1903080
    [Abstract] [Full Text] [Related]

  • 23. Short-term intravenous eptifibatide infusion combined with reduced dose recombinant tissue plasminogen activator inhibits platelet recruitment at sites of coronary artery injury.
    Rubenstein MH, Finn AV, Leinbach RC, Hollenbach S, Aretz HT, Virmani R, Gold HK.
    J Am Coll Cardiol; 2004 Jan 21; 43(2):287-94. PubMed ID: 14736451
    [Abstract] [Full Text] [Related]

  • 24. Evaluation of thrombolytic and systemic effects of the novel recombinant plasminogen activator BM 06.022 compared with alteplase, anistreplase, streptokinase and urokinase in a canine model of coronary artery thrombosis.
    Martin U, Sponer G, Strein K.
    J Am Coll Cardiol; 1992 Feb 21; 19(2):433-40. PubMed ID: 1732372
    [Abstract] [Full Text] [Related]

  • 25. Recombinant lys-plasminogen, but not glu-plasminogen, improves recombinant tissue-type plasminogen activator-induced coronary thrombolysis in dogs.
    Mehta JL, Chen L, Nichols WW, Johannesen M, Bregengård C, Hedner U, Saldeen TG.
    J Am Coll Cardiol; 1995 Mar 01; 25(3):753-60. PubMed ID: 7860925
    [Abstract] [Full Text] [Related]

  • 26. The thrombolytic effects of native tissue-type plasminogen activator (AK-124) on experimental canine coronary thrombosis.
    Tomaru T, Uchida Y, Sonoki H, Tsukamoto M, Sugimoto T.
    Angiology; 1989 May 01; 40(5):429-35. PubMed ID: 2495745
    [Abstract] [Full Text] [Related]

  • 27. Oxygen radical scavenging agents as adjuvant therapy with tissue plasminogen activator in a canine model of coronary thrombolysis.
    Przyklenk K, Kloner RA.
    Cardiovasc Res; 1993 Jun 01; 27(6):925-34. PubMed ID: 8221780
    [Abstract] [Full Text] [Related]

  • 28. Sustained reflow in dogs with coronary thrombosis with K2P, a novel mutant of tissue-plasminogen activator.
    Nicolini FA, Nichols WW, Mehta JL, Saldeen TG, Schofield R, Ross M, Player DW, Pohl GB, Mattsson C.
    J Am Coll Cardiol; 1992 Jul 01; 20(1):228-35. PubMed ID: 1607530
    [Abstract] [Full Text] [Related]

  • 29. Prevention of thrombosis and rethrombosis and enhancement of the thrombolytic actions of recombinant tissue-type plasminogen activator in the canine heart by DMP728, a glycoprotein IIb/IIIa antagonist.
    Lucchessi BR, Rote WE, Driscoll EM, Mu DX.
    Br J Pharmacol; 1994 Dec 01; 113(4):1333-43. PubMed ID: 7889289
    [Abstract] [Full Text] [Related]

  • 30. Antithrombotic efficacy of single subcutaneous administration of a recombinant nematode anticoagulant peptide (rNAP5) in a canine model of coronary artery thrombolysis.
    Rebello SS, Blank HS, Lucchesi BR.
    Thromb Res; 2000 Jun 15; 98(6):531-40. PubMed ID: 10899352
    [Abstract] [Full Text] [Related]

  • 31. Hirudin and sulotroban improve coronary blood flow after reperfusion induced by the novel recombinant plasminogen activator BM 06.022 in a canine model of coronary artery thrombosis.
    Martin U, Sponer G, Strein K.
    Int J Hematol; 1992 Oct 15; 56(2):143-53. PubMed ID: 1421176
    [Abstract] [Full Text] [Related]

  • 32. Prevention of coronary artery reocclusion and reduction in late coronary artery stenosis after thrombolytic therapy in patients with acute myocardial infarction. A randomized study of maintenance infusion of recombinant human tissue-type plasminogen activator.
    Johns JA, Gold HK, Leinbach RC, Yasuda T, Gimple LW, Werner W, Finkelstein D, Newell J, Ziskind AA, Collen D.
    Circulation; 1988 Sep 15; 78(3):546-56. PubMed ID: 3136953
    [Abstract] [Full Text] [Related]

  • 33. Pharmacokinetic and thrombolytic properties of unglycosylated recombinant tissue-type plasminogen activator (BM 06.021) produced in Escherichia coli.
    Martin U, Fischer S, Kohnert U, Opitz U, Rudolph R, Sponer G, Stern A, Strein K.
    Naunyn Schmiedebergs Arch Pharmacol; 1992 Jul 15; 346(1):108-13. PubMed ID: 1407000
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Pharmacokinetics and thrombolytic properties of a nonglycosylated mutant of human tissue-type plasminogen activator, lacking the finger and growth factor domains, in dogs with copper coil-induced coronary artery thrombosis.
    Cambier P, van de Werf F, Larsen GR, Collen D.
    J Cardiovasc Pharmacol; 1988 Apr 15; 11(4):468-72. PubMed ID: 2453751
    [Abstract] [Full Text] [Related]

  • 36. Enhanced myocardial salvage by combined treatment with recombinant single-chain urokinase-type plasminogen activator and recombinant human superoxide dismutase in a canine coronary thrombosis model.
    Fincke U, Schneider J, Friderichs E, Giertz H, Flohé L.
    Arzneimittelforschung; 1988 Jan 15; 38(1):138-42. PubMed ID: 3365272
    [Abstract] [Full Text] [Related]

  • 37. Prevention of rethrombosis after coronary thrombolysis in a chronic canine model. I. Adjunctive therapy with monoclonal antibody 7E3 F(ab')2 fragment.
    Rote WE, Mu DX, Bates ER, Nedelman MA, Lucchesi BR.
    J Cardiovasc Pharmacol; 1994 Feb 15; 23(2):194-202. PubMed ID: 7511747
    [Abstract] [Full Text] [Related]

  • 38. Maintenance of canine coronary artery patency following thrombolysis with front loaded plus low dose maintenance conjunctive therapy. A comparison of factor Xa versus thrombin inhibition.
    Lynch JJ, Sitko GR, Mellott MJ, Nutt EM, Lehman ED, Friedman PA, Dunwiddie CT, Vlasuk GP.
    Cardiovasc Res; 1994 Jan 15; 28(1):78-85. PubMed ID: 8111795
    [Abstract] [Full Text] [Related]

  • 39. Coronary arterial thrombolysis with low-dose synergistic combinations of recombinant tissue-type plasminogen activator (rt-PA) and recombinant single-chain urokinase-type plasminogen activator (rscu-PA) for acute myocardial infarction.
    Collen D, Van de Werf F.
    Am J Cardiol; 1987 Sep 01; 60(7):431-4. PubMed ID: 3115077
    [Abstract] [Full Text] [Related]

  • 40. Vampire bat salivary plasminogen activator promotes rapid and sustained reperfusion without concomitant systemic plasminogen activation in a canine model of arterial thrombosis.
    Mellott MJ, Stabilito II, Holahan MA, Cuca GC, Wang S, Li P, Barrett JS, Lynch JJ, Gardell SJ.
    Arterioscler Thromb; 1992 Feb 01; 12(2):212-21. PubMed ID: 1371932
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.